Summary
Eli Lilly and Company (LLY) filed an 8-K on July 25, 2017, to report its financial results for the second quarter and six-month period ended June 30, 2017. The filing primarily incorporates by reference a press release detailing these operational and financial outcomes. Investors should refer to the attached Exhibit 99.1 for the specific financial performance details. While this 8-K serves as a notification of the release of Q2 2017 results, it does not contain the detailed financial statements or management's discussion and analysis directly within the 8-K form itself. The comprehensive financial data and commentary are provided in the press release attached as Exhibit 99.1. Investors seeking to understand Lilly's performance in the second quarter of 2017 will need to consult this accompanying document for key metrics such as revenue, earnings per share, and segment performance.
Key Highlights
- 1Eli Lilly & Co. (LLY) filed an 8-K on July 25, 2017.
- 2The filing announces the company's results of operations for the second quarter and six-month period ended June 30, 2017.
- 3Key financial information is provided through an attached press release (Exhibit 99.1).
- 4The press release details unaudited operating results for the reported periods.
- 5Information furnished under Item 2.02 is not deemed 'filed' for Section 18 purposes, limiting liabilities.
- 6The 8-K primarily serves as a notification mechanism for the release of quarterly financial results.
- 7Investors are directed to Exhibit 99.1 for the specific Q2 2017 financial performance data.